Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
RELYVRIO (previously known as AMX0035 in the U.S.) is an oral, fixed-dose combination therapy for the treatment of adults with ALS RELYVRIO significantly slowed loss of physical function in a randomized, placebo-controlled clinical trial in ALS Detailed data from the CENTAUR clinical trial were published in the New England Journal of Medicine, Muscle & Nerve, … [Read more…]
